Closing the data loop in AI-driven drug discovery
Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…
Record details
Published: 27 July 2026
Source: MIT Technology Review
Category: News
Topics: Regulation · Healthcare · Biotech
Retrieved: 28 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
The path to artificial superintelligence
MIT Technology Review · 27 July 2026
How AI helps scientists design the next generation of medicines
MIT Technology Review · 23 July 2026
Biotech giant Amgen says patient data stolen from third-party cloud systems
The Record (Recorded Future News) · 3 August 2026
India’s drug regulator has not adopted AI for regulatory approvals: Govt
MediaNama (IN) · 6 August 2026
Nearly 200 Organizations Back Bill To Expand Access To Clinical Trials
Above the Law (legal tech) · 15 July 2026
Bipartisan Lawmakers Are Fighting HHS’ 340B Rebate Push
Above the Law (legal tech) · 11 August 2026
How to cite this record
ethics.ai (27 July 2026), “Closing the data loop in AI-driven drug discovery,” evidence record 13753, https://ethics.ai/record/13753 (originally published by MIT Technology Review).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.